Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...

Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...

(CNN) — Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity ...

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...